LS
Lisata Therapeutics, Inc.
LSTA · NASDAQ
$1.70 -0.58% (-$0.01)
1M +9.68%
Market Cap $15.8M
P/E Ratio -
Div. Yield -
ROE 113.79%
Piotroski F-Score Weak
1/9Valuation
45 /100
Fair P/B 1.92x
P/S 158.45x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 39.35%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 16,427.00%
Gross margin 95.00%
FCF margin 12,323.00%
Quality
0 /100
Poor ROA 132.59%
ROIC 199.05%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 3.69x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
61 /100
Moderate Profitable years 0
Beta 0.80x
EPS volatility 36.23%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o LSTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David J. Mazzo
Employees
21
Headquarters
Basking Ridge
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report